Drug Trial Radar · NCT04938583
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Mar 17, 2021
Primary completion
Oct 30, 2025
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- CanariaBio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Korean Cancer Study Group
- First posted
- Jun 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single arm phase 1b/2 evaluation of the combination of oregovomab, and bevacizumab, paclitaxel carboplatin in adult subjects with CA125-associated, advanced recurrent epithelial ovarian, fallopian tube or peritoneal carcinoma (FIGO Stage III/IV) with BRCA-wild type, previously treated with 1 prior lines of therapy, and with platinum free intervals of \>6 months since last platinum-based treatment.
Conditions
- Ovarian Cancer by FIGO Stage
- Ovarian Cancer Stage III
- Ovarian Cancer Stage IV
Interventions
OregovomabBiological
Oregovomab will be administered on day1 cycle 1, 3, 5, and 9. A minimum of 3 patients will be enrolled into each cohort (2 mg or 1 mg). 2 mg (starting dose), dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
BevacizumabDrug
15mg/Kg Day 1 (every 21 days) until progression
PaclitaxelDrug
175 mg/m\^2, Day 1 x 6 cycles (every 21 days)
CarboplatinDrug
AUC 5 IV Day 1 x 6 cycles (every 21 days)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: 1cycle (21days)
- Efficacy based on overall response rate (ORR)Time frame: Every 6 weeks (each cycle is 21 days)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Kyungpook National University Chilgok Hospital
Daegu, South Korea
CHA Bundang Medical Center
Seongnam-si, South Korea
Severance Hospital
Seoul, South Korea
Korea Anam Hospital
Seoul, Seoul, South Korea
Asan Medical Hospital
Seoul, Seoul, South Korea
Seoul St. Mary's Hospital
Seoul, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.